2ieme edition. Ce guide présente un ensemble standardisé d'indicateurs pour le suivi et l'évaluation des programmes de communication pour le changement social et comportemental (CCS) ciblant la lutte contre le paludisme. Basée sur la première édition, publiée en 2014, cette deuxième édition... propose un ensemble plus rationalisé d'indicateurs prioritaires et inclut les prestataires de soins de santé comme public cible. Elle élargit également l'éventail des sources de données au-delà des enquêtes auprès des ménages
more
Clinical Pharmacology: Advances and Applications, 2025:17 29–47
Preferred product characteristics and clinical development considerations
Deux vaccins antipaludiques sont actuellement préqualifiés et recommandés par l'OMS1 pour prévenir
le paludisme à P. falciparum chez les jeunes enfants : le vaccin RTS,S/AS01, actuellement fabriqué par
GlaxoSmithKline (GSK), et le vaccin R21/Matrix-M, fabriqué par Serum Institute of India
...Pvt (SII).
more
Le Plan Stratégique National de Lutte contre le Paludisme 2023–2026 du Togo définit les grandes orientations pour réduire de 65 % l’incidence et la mortalité liées au paludisme d’ici 2026, en comparaison avec les niveaux de 2022. Élaboré par le Programme National de Lutte contre le Pa...ludisme (PNLP), il s’inscrit pleinement dans les objectifs mondiaux fixés par l’Organisation mondiale de la Santé pour parvenir à l’élimination du paludisme d’ici 2030. Ce plan repose sur quatre axes stratégiques : la prévention à travers l’utilisation des moustiquaires imprégnées, la chimio-prévention et la lutte antivectorielle ; la prise en charge efficace des cas grâce au diagnostic rapide et au traitement par ACT ; le renforcement du système de santé et la gestion du programme ; ainsi que la surveillance, le suivi et l’évaluation des interventions. Une attention particulière est accordée à la digitalisation des outils, à l’amélioration de la qualité des données, à l’implication des communautés locales et à la réduction des inégalités régionales dans l’accès aux services. Intégrant les partenaires techniques et financiers, le secteur privé et les acteurs communautaires, ce document constitue une véritable feuille de route nationale pour coordonner et intensifier la lutte contre le paludisme sur la période 2023–2026.
more
This document on logistics management information systems (LMIS) was developed to address the increasing need for harmonization and standardization of core indicators for managing medicines and health products for neglected tropical diseases (NTDs) at country level (i.e. for last-mile logistics). It... thereby responds to requests from Members States, pharmaceutical groups, financial donors and implementing partners for guidance from the World Health Organization (WHO) for a transparent, standardized reporting mechanism and key indicators for in-country logistics. More importantly, this document will also guide the last-mile logistics process and is relevant for the health workforce working at different levels of national health information systems. It can be adapted and used for any health products depending on the needs of the country or health programmes.
more
Plos Neglected Tropical Diseases 8(11): e3229 (20 November 2014)
Policy
July 2012
Working Paper No. 3
Biennial Report. SUBMITTED TO THE UNITED NATIONS GENERAL ASSEMBLY SPECIAL SESSION ON HIV AND AIDS
Reporting period: January 2012 – December 2013
The goal of this course is to provide participants with the foundational skills needed to begin the development, implementation and ongoing improvement of a congenital anomalies surveillance programme, in particular for countries with limited resources. It focuses on the methodology needed to devel...op either population-based or hospital based surveillance programmes.
A set of congenital anomalies will be used as examples throughout this course. The specific examples used are typically severe enough that they would probably be captured within the first few days after birth, have a significant public health impact and, for some of them, have the potential for primary prevention.
more
CYCLE DE PROGRAMMATION HUMANITAIRE 2020-2022
Ce document est consolidé par OCHA pour le compte de l’Équipe humanitaire pays et des partenaires humanitaires. Il présente les priorités et les paramètres de la réponse stratégique de l’Équipe humanitaire pays, basés sur une compréhension ...partagée de la situation.
more
The figures and findings reflected in the 2020 PMR represent the independent analysis of the United Nations (UN) and its humanitarian partners based on information available to them. Many of the figures provided throughout the document are estimates based on sometimes incomplete and partial data set...s using the methodologies for collection that were available at the time. The Government of Syria has expressed its reservations over the data sources and methodology of assessments used to inform the 2020 Humanitarian Needs Overview (HNO) as well as on a number of HNO findings reflected in the 2020 HRP. This applies throughout the document.
more
The Practical manual on laboratory strengthening, 2022 update provides practical guidance on implementation of WHO recommendations and best practices for TB laboratory strengthening. It is an updated version of the GLI Practical Guide to Laboratory Strengthening published in 2017 and provides the la...test practical guidance on use of newly recommended diagnostics as well as guidance in key technical areas, including quality assurance and quality management systems, specimen collection and registration, procurement and supply-chain management, diagnostic connectivity, biosafety, data management, human resources, strategic planning, and model algorithms. The key changes are:
inclusion of recent or updated WHO recommendations for tests to diagnose TB and detect drug resistance;
alignment with the latest WHO critical concentrations for phenotypic drug-susceptibility testing (DST) and the new definitions of pre-XDR-TB and XDR-TB;
updated information on building quality-assured TB testing and management capacity using the Stepwise Laboratory Quality Improvement Process Towards Accreditation (SLIPTA) approach (Score-TB package1);
updated information on assessing, analysing and optimising TB diagnostic networks; and
updated information on the use of next-generation sequencing (NGS) to detect mutations associated with drug resistance for surveillance purposes.
The document also provides references to resources and tools relevant for work on laboratory strengthening.
more
World Drug Report 2018
-3-
Jamieson D and Kellerman S. Journal of the International AIDS Society 2016, 19:20917 http://www.jiasociety.org/index.php/jias/article/view/20917 | http://dx.doi.org/10.7448/IAS.19.1.20917